PBI selectively pursues collaborations to accelerate the commercialization of its pipeline. The Company also welcomes the opportunity to discuss with potential partners, the ways that its technology can help to create the next breakthrough medicine.
PBI’s BioSynersys™ and ProbioTherapeutic™ platform technologies along with its process know-how are available to partners for the development of next generation therapeutics. Working with PBI offers access to its unique Synergy PEG reagents.
In instances where a promising product suffers disappointment after applying conventional Pegylation, a valuable product is limited by the current Pegylation method, or a product encounters any of the problems, such as short half-life, frequent or high dosing, toxicity, immunogenicity, stability, and solubility, PBI is able to offer a solution that could help partners realize the full potential of their products.
Product & Technology Partnership Opportunities:
PBI’s two core products and BioSynersys™ technology platform are available for partnership opportunities:
PB307 opens up a new realm of anticancer immunotherapy. PB307 has the potential to be a powerful immune-oncology drug. In addition to inhibiting tumor growth without drug resistance and adverse effects, the PB307 formula offers other advantages as an immunotherapeutic drug:
· PB307 could be an effective immunotherapeutic drug for prophylaxis of cancer recurrence.
· PB307 has potential to be an anticancer drug with multiple cancer indications, including pancreatic cancer, colorectal cancer, gastric cancer, lung cancer, gastric cancer, head and neck cancer, ovarian cancer, lung cancer, etc.
PB1103, a synergy interferon-alfa, has increased, sustained and prolonged biological activity in blood plasma. PB1103 is expected to be an effective biotherapy for the treatment of various cancers, including kidney, melanoma, Kaposi sarcoma, hairy cell leukemia (HCL), myeloid leukemia (CML) and hematologic cancers. PB1103 could be an effective medicine for the treatment of blood diseases, such as polycythaemia vera (PCV), essential thrombocythemia (ET), etc. PB1103 provides synergistically increased antiviral activity and enhanced pharmacological properties and has been demonstrated to be superior to the commercial Pegylated interferon-alfa in animal studies.
PBI’s BioSynersys™ technology is available for partnership or licensing for application to biological drugs to develop new generation Synergy PEG-enhanced drugs with the potential to be the next breakthrough therapeutic.
PBI’s ProbioTherapeutic™ technology is a new site-specific conjugation technology that provides (i) retention of 100% activity of biologics in vivo, (ii) increased biologics’ bioavailability in blood plasma, (iii) increased solubility of biologics, (iv) improved stability of biologics, and (v) increased half-life of biologics. ProbioTherapeutic™ technology is available for licensing and partnership for application to peptides and biologics to develop improved drug formulations and potentially develop the next breakthrough therapeutics.
PEG Biosciences is proud of working with our strategic partners to ensure the best expertise is applied to our technologies and drug development.
Rutgers Cancer Institute of New Jersey (CINJ).
Rutgers Cancer Institute of New Jersey is the National Cancer Institute-designated Comprehensive Cancer Center and is recognized as one of the nation’s premier research and clinical cancer treatment centers. PEG Biosciences works with CINJ in the area of immuno-oncology to transform research into clinical medicine.
Rutgers Brain Health Institute (BHI) and Rutgers Endocrine Research.
The BHI is an interdisciplinary institute at Rutgers University, and has outstanding strength and a broad range of research interests in the area of neurodegeneration, motivational & affective neuroscience, cognitive & sensory neuroscience, and neurodevelopment. PEG Biosciences works with BHI and Endocrine Research to develop medicines for the treatment of disease-related neuroscience, including pain, opioids and alcohol addictions, neuro disorders and neurodegenerative diseases.
Tulane Microbiology, Immunology and Virology Department /Tulane National Primate Research Center.
Tulane National Primate Research Center (TNPRC) improves human and animal health through basic and applied biomedical research. As one of the seven National Primate Research Centers funded by the National Institute of Health, the TNPRC is committed to discovering causes, preventions, treatments, and cures that allow people around the world to live longer, healthier lives.
Business Development and Partnerships